+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gabapentin Market - Global Forecast 2026-2032- Product Image
Gabapentin Market - Global Forecast 2026-2032- Product Image
New

Gabapentin Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 192 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 6016490
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The gabapentin market is evolving as clinical applications, supply chains, and regulatory landscapes reshape strategies for manufacturers, healthcare providers, and procurement leaders. Senior decision-makers must navigate operational risks, competitive differentiation, and an increasingly dynamic patient access environment.

Gabapentin Market Snapshot

The gabapentin market grew from USD 2.43 billion in 2025 to USD 2.53 billion in 2026. It is expected to continue growing at a CAGR of 4.50%, reaching USD 3.30 billion by 2032. This robust market trajectory reflects expanding usage in neurological care, ongoing formulation improvements, and responsive commercial strategies in the face of regulatory changes and global supply pressures. Current business priorities underline operational resilience and product innovation to meet evolving stakeholder needs.

Scope & Segmentation: Strategic Layers in the Gabapentin Market

  • Administration Routes: Analysis of oral versus parenteral administration impacts formulation development and hospital inventory management.
  • Formulation Types: Distinction between branded options with proprietary features and generics focusing on cost and scale.
  • Dosage Forms: Includes capsules (hard and soft gelatin), oral solutions, and tablets (extended- and immediate-release) that affect adherence and packaging.
  • Distribution Channels: Hospital, retail, and online pharmacy segments, each with unique inventory, contracting, and compliance protocols.
  • End Users: Clinics, home care, and hospitals, each with varying administration oversight and reimbursement structures.
  • Clinical Indications: Coverage across epilepsy, neuropathic pain (such as diabetic neuropathy and postherpetic neuralgia), and restless leg syndrome, driving unique clinical evidence demands.
  • Regional Dynamics: Americas, Europe, Asia-Pacific, and Middle East & Africa—each region characterized by different regulatory frameworks, manufacturing hubs, and procurement models.
  • Technology & Innovation: Focus on extended-release dosage forms, soft gel capsules, digital health integration, and portfolio-optimization strategies to enhance patient support and product lifecycle.

Key Takeaways for Decision-Makers

  • Gabapentin has expanded from seizure management into broader neurological and pain indications, requiring continual evolution of formulations to support adherence and tolerability.
  • Generic market maturation compels manufacturers to move beyond price competition, using patient-centric features and extended-release technologies to differentiate their portfolios.
  • Safety remains central, as regulatory reviews and post-market surveillance address off-label use and risks related to concomitant opioid therapies, necessitating strong pharmacovigilance.
  • Distribution channels are adapting to digital trends, with telemedicine and online pharmacy growth transforming patient access, inventory turn, and reimbursement practices.
  • Regional supply chain strategies—such as diversification of active pharmaceutical ingredient (API) sources and enhanced quality assurance—help stakeholders manage quality risks and shifting geopolitical trade dynamics.
  • Pharmaceutical partnerships and licensing broaden product offerings, while investments in real-world evidence and clinical education support regulatory compliance and payer engagement.

Tariff Impact on Procurement and Supply Chain Continuity

Cumulative tariff shifts in 2025 have triggered reevaluation of procurement strategies, manufacturing sites, and supplier networks. Companies are advancing dual-sourcing agreements and expanding regional manufacturing to reduce cost exposure and ensure supply security. Transparent contracting and contingent supply clauses are becoming standard among payers and institutional purchasers. Regulatory teams now prioritize documentation of country-of-origin and importation pathways, aiming for seamless customs clearance and uninterrupted supply continuity.

Market Research Methodology & Data Sources

This report’s foundation lies in a robust mixed-methods research approach. Structured consultations with clinicians, procurement leads, and regulatory experts supplement peer-reviewed research, regulatory documents, and supply chain intelligence. Data triangulation and segmentation mapping ensure validated insights across all major regions and segments.

Why This Gabapentin Market Report Matters

  • Enables proactive scenario planning to fortify supply resilience against regulatory and market fluctuations.
  • Equips commercial leaders with actionable intelligence for product differentiation, risk mitigation, and effective channel strategies.
  • Supports safe clinical use and compliance with emerging digital, regulatory, and distribution demands.

Conclusion

Success in the gabapentin market hinges on balancing clinical value, operational agility, and regulatory vigilance. Strategic investments in differentiated formulations, risk management, and digital-enabled distribution will sustain growth and patient care outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Gabapentin Market, by Route Of Administration
8.1. Oral
8.2. Parenteral
9. Gabapentin Market, by Formulation
9.1. Branded
9.2. Generic
10. Gabapentin Market, by Dosage Form
10.1. Capsules
10.1.1. Hard Gelatin
10.1.2. Soft Gelatin
10.2. Oral Solution
10.3. Tablets
10.3.1. Extended Release
10.3.2. Immediate Release
11. Gabapentin Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Gabapentin Market, by End User
12.1. Clinics
12.2. Home Care
12.3. Hospitals
13. Gabapentin Market, by Indication
13.1. Epilepsy
13.2. Neuropathic Pain
13.2.1. Diabetic Neuropathy
13.2.2. Postherpetic Neuralgia
13.3. Restless Leg Syndrome
14. Gabapentin Market, by Region
14.1. Americas
14.1.1. North America
14.1.2. Latin America
14.2. Europe, Middle East & Africa
14.2.1. Europe
14.2.2. Middle East
14.2.3. Africa
14.3. Asia-Pacific
15. Gabapentin Market, by Group
15.1. ASEAN
15.2. GCC
15.3. European Union
15.4. BRICS
15.5. G7
15.6. NATO
16. Gabapentin Market, by Country
16.1. United States
16.2. Canada
16.3. Mexico
16.4. Brazil
16.5. United Kingdom
16.6. Germany
16.7. France
16.8. Russia
16.9. Italy
16.10. Spain
16.11. China
16.12. India
16.13. Japan
16.14. Australia
16.15. South Korea
17. United States Gabapentin Market
18. China Gabapentin Market
19. Competitive Landscape
19.1. Market Concentration Analysis, 2025
19.1.1. Concentration Ratio (CR)
19.1.2. Herfindahl Hirschman Index (HHI)
19.2. Recent Developments & Impact Analysis, 2025
19.3. Product Portfolio Analysis, 2025
19.4. Benchmarking Analysis, 2025
19.5. Alkem Laboratories Ltd.
19.6. Amneal Pharmaceuticals Inc.
19.7. Apotex Inc.
19.8. Ascend Laboratories LLC
19.9. Aurobindo Pharma Limited
19.10. Cadila Healthcare Ltd.
19.11. Cipla Limited
19.12. Dr. Reddy's Laboratories Ltd.
19.13. Emcure Pharmaceuticals Ltd.
19.14. Endo International plc
19.15. Glenmark Pharmaceuticals Ltd.
19.16. Granules India Limited
19.17. Hikma Pharmaceuticals PLC
19.18. Intas Pharmaceuticals Ltd.
19.19. Lupin Limited
19.20. Pfizer Inc.
19.21. Sandoz (a Novartis division)
19.22. Strides Pharma Science Ltd
19.23. Sun Pharmaceutical Industries Ltd.
19.24. Teva Pharmaceutical Industries Ltd.
19.25. Torrent Pharmaceuticals Ltd.
19.26. Viatris Inc.
19.27. Zydus Lifesciences Limited
List of Figures
FIGURE 1. GLOBAL GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL GABAPENTIN MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL GABAPENTIN MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 13. UNITED STATES GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 14. CHINA GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL GABAPENTIN MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL GABAPENTIN MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL GABAPENTIN MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL GABAPENTIN MARKET SIZE, BY HARD GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL GABAPENTIN MARKET SIZE, BY SOFT GELATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL GABAPENTIN MARKET SIZE, BY ORAL SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL GABAPENTIN MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL GABAPENTIN MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL GABAPENTIN MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL GABAPENTIN MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL GABAPENTIN MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL GABAPENTIN MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL GABAPENTIN MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY REGION, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL GABAPENTIN MARKET SIZE, BY EPILEPSY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL GABAPENTIN MARKET SIZE, BY DIABETIC NEUROPATHY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL GABAPENTIN MARKET SIZE, BY POSTHERPETIC NEURALGIA, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL GABAPENTIN MARKET SIZE, BY RESTLESS LEG SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL GABAPENTIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. AMERICAS GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 79. AMERICAS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 80. AMERICAS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 88. NORTH AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 89. NORTH AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 90. NORTH AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 98. LATIN AMERICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 99. LATIN AMERICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 100. LATIN AMERICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 108. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 118. EUROPE GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 119. EUROPE GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 120. EUROPE GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 121. EUROPE GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 122. EUROPE GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 123. EUROPE GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 124. EUROPE GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 125. EUROPE GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 126. EUROPE GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 127. EUROPE GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 128. MIDDLE EAST GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 129. MIDDLE EAST GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 130. MIDDLE EAST GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 138. AFRICA GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 139. AFRICA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 140. AFRICA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 141. AFRICA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 142. AFRICA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 143. AFRICA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 144. AFRICA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 145. AFRICA GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 146. AFRICA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 147. AFRICA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 148. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 149. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 150. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 158. GLOBAL GABAPENTIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 159. ASEAN GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. ASEAN GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 161. ASEAN GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 162. ASEAN GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 163. ASEAN GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 164. ASEAN GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 165. ASEAN GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 166. ASEAN GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 167. ASEAN GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 168. ASEAN GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 169. GCC GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. GCC GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 171. GCC GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 172. GCC GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 173. GCC GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 174. GCC GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 175. GCC GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 176. GCC GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 177. GCC GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 178. GCC GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 179. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 189. BRICS GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 190. BRICS GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 191. BRICS GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 192. BRICS GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 193. BRICS GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 194. BRICS GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 195. BRICS GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 196. BRICS GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 197. BRICS GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 198. BRICS GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 199. G7 GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 200. G7 GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 201. G7 GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 202. G7 GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 203. G7 GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 204. G7 GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 205. G7 GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 206. G7 GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 207. G7 GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 208. G7 GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 209. NATO GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 210. NATO GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 211. NATO GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 212. NATO GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 213. NATO GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 214. NATO GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 215. NATO GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 216. NATO GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 217. NATO GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 218. NATO GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 219. GLOBAL GABAPENTIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 220. UNITED STATES GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 221. UNITED STATES GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 222. UNITED STATES GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)
TABLE 230. CHINA GABAPENTIN MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 231. CHINA GABAPENTIN MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 232. CHINA GABAPENTIN MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 233. CHINA GABAPENTIN MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 234. CHINA GABAPENTIN MARKET SIZE, BY CAPSULES, 2018-2032 (USD MILLION)
TABLE 235. CHINA GABAPENTIN MARKET SIZE, BY TABLETS, 2018-2032 (USD MILLION)
TABLE 236. CHINA GABAPENTIN MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 237. CHINA GABAPENTIN MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 238. CHINA GABAPENTIN MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 239. CHINA GABAPENTIN MARKET SIZE, BY NEUROPATHIC PAIN, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Gabapentin market report include:
  • Alkem Laboratories Ltd.
  • Amneal Pharmaceuticals Inc.
  • Apotex Inc.
  • Ascend Laboratories LLC
  • Aurobindo Pharma Limited
  • Cadila Healthcare Ltd.
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Emcure Pharmaceuticals Ltd.
  • Endo International plc
  • Glenmark Pharmaceuticals Ltd.
  • Granules India Limited
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Lupin Limited
  • Pfizer Inc.
  • Sandoz (a Novartis division)
  • Strides Pharma Science Ltd
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited

Table Information

Report AttributeDetails
No. of Pages192
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.53 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.3 Billion
Compound Annual Growth Rate4.5%
Regions CoveredGlobal
No. of Companies Mentioned24

Related Topics

Related Reports

Gabapentin - Global Strategic Business Report - Product Image

Gabapentin - Global Strategic Business Report

  • Report
  • 477 Pages
  • Global
From
Gabapentin Global Market Report 2025 - Product Image

Gabapentin Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Gabapentin Market Report and Forecast 2025-2034 - Product Image

Gabapentin Market Report and Forecast 2025-2034

  • Report
  • 350 Pages
  • Global
From
Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Gabapentin Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

Gabapentin Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 99 Pages
  • Global
From

About the Gabapentin Market

Gabapentin is a medication used to treat certain types of seizures and nerve pain. It is a central nervous system (CNS) drug, meaning it acts on the brain and spinal cord to produce its effects. It is used to treat epilepsy, neuropathic pain, hot flashes, and restless leg syndrome. It is also used off-label to treat anxiety and insomnia. Gabapentin is generally well-tolerated, but can cause side effects such as dizziness, drowsiness, and confusion. Gabapentin is available in both generic and brand-name forms. It is available in capsule, tablet, and oral solution forms. It is also available as an extended-release tablet, which is taken once daily. The market for Gabapentin is highly competitive, with many companies offering generic and brand-name versions of the drug. Some of the companies in the market include Pfizer, Mylan, Teva Pharmaceuticals, Sun Pharmaceuticals, and Lupin Pharmaceuticals. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.